Stem Cell Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Stem Cell Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cord Blood
Researchers from Sydney Children's Hospital report details of new studies and findings in the area of cord blood
August 25th, 2008
"Ex vivo expansion of cord blood cells generally results in reduced stem cell activity in vivo. Glycogen synthase kinase-3 beta (GSK-3 beta) regulates the degradation of beta-catenin, a critical regulator of hematopoietic stem cells (HSCs)," scientists writing in the journal Stem Cells report. "Here we show that GSK-3 beta inhibition activates beta-catenin in cord blood CD34(+) cells and upregulates beta-catenin transcriptional targets c-myc and HoxB4, both known to regulate HSC self-renewal. GSK-3 beta inhibition resulted in delayed ex vivo expansion of CD34(+) cells, yet enhanced the preservation of stem cell activity as tested in long-term culture with bone...
Source: Stem Cell Week (2008-08-25)
|
